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Summary The activity of a new nitrosourea (TCNU) based on the endogenous amino acid taurine was
assessed in three human lung cancer xenografts growing in immunodeficient mice. Moderate activity (specific
growth delays of 0.63 and 1.13 compared with controls) was seen in two non-small cell tumours after a single
oral administration of 20 mg-1kg. This dose was curative in a small cell xenograft. By using high performance
liquid chromatography it was possible to detect parent drug in the tumours as well as the plasma and tissues
after oral administration of TCNU. Drug sensitivity was correlated inversely with the amount of the DNA
repair enzyme 06-methylguanine-DNA methyltransferase assayed from extracts of the tumour cells but not
with the levels of parent drug within the tumour. This compound appears to have unique pharmacokinetic
properties compared with other chloroethylnitrosoureas.
Chloroethylnitrosoureas have been used as anti-cancer treat-
ments for many years. The initial enthusiasm generated by
impressive activity in preclinical screening models has been
tempered by modest anti-tumour activity in man and the
problem of delayed cumulative myelosuppression (Weiss &
Issell, 1982; Mitchell & Schein, 1986). Despite this they have
been used in a number of malignancies and their ability to
cross the blood-brain barrier has led to interest in their
activity against malignant gliomas (Walker et al. 1980).
Unfortunately little is known of the pharmacokinetics of the
nitrosoureas as it is only recently that techniques have been
available to study the plasma levels of the parent drugs and
their metabolites (Lee et al., 1985).
The cytotoxicity of the nitrosoureas is thought to be
mediated predominantly by the alkylation of reactive sites on
nuclear proteins and by the production of lethal interstrand
DNA crosslinks through an 06 alkylguanine intermediate
(Tong, et al., 1982). Repair of these intermediates is carried
out by 06-methylguanine-DNA methyltransferase (Robins et
al., 1983) and cells deficient in this enzyme (Mer- cells) are
more sensitive to damage by chloroethylating agents
(Scudiero et al., 1984). Structure-activity studies have shown
considerable variation amongst different nitrosoureas and
recently attempts have been made to improve the therapeutic
index of the nitrosoureas by producing analogues with novel
carrier groups (Johnston & Montgomery, 1986).
TCNU [1-(2-chloroethyl)-3-[2-dimethylamino-sulphonyl)-
ethyl]- 1-nitrosourea] is a new chloroethyl nitrosourea
based on the endogenous amino acid taurine. It appears to
have unique pharmacokinetic properties compared with
other nitrosoureas with the parent drug being detectable in
the plasma for up to 8 h following oral administration in
man (Gunnarson et al., 1988; Smyth et al., 1987). Other
nitrosoureas such as CCNU cannot be detected in the
plasma (Lee et al., 1985). Anti-tumour activity has been
reported in vitro against human colonic and small cell lung
cancer cell lines (Roed et al., 1987; Hartley-Asp et al.,
1988) and in vivo against a variety of transplantable murine
tumours (Bibby & Double, 1987; Hartley-Asp et al., 1988).
No studies describing its activity in vivo against human
tumours have yet been reported.
The validity of a human tumour system for assessing
drugs in lung cancer has been established by direct
xenograft-patient comparisons (Shorthouse et al., 1980). We
have tested the effectiveness of oral TCNU in three human
lung cancer xenografts grown in neonatally thymectomised,
irradiated mice. The levels of the DNA repair protein
06 methylguanine-DNA methyltransferase were assayed in
extracts from the tumours. Using reversed phase high
performance liquid chromatography (HPLC) the levels of the
parent drug were measured in plasma, host tissues and
tumours.
Materials and methods
Immunosuppressed mice
Thymectomy was performed by retrosternal aspiration on 3
week old male CBA/Lac mice shortly after weaning. Three
weeks later they underwent whole body X-irradiation
(7.35Gy via a 250kVp, 15mA source with a Thoraeus Ii
filter at 0.37Gymin-I +2%). Cytosine arabinoside
200 mgkg 1 i.p. was given 48 h prior to irradiation to
protect the bone marrow and gastrointestinal tract. Human
bronchial tumour fragments (I mm3) were implanted sub-
cutaneously into each flank the day following irradiation.
Neomycin and terramycin were added to the drinking water
for the next 14 days to reduce the incidence of septicaemia
from gut flora. The animals were housed in conventional
conditions in a separate room in the animal unit.
Tumour xenografts
Three human bronchial tumours were used for drug testing,
their growth characteristics have been described previously
(Fergusson et al., 1986). (i) CX117 a poorly differentiated
adenocarcinoma obtained at thoracotomy, (ii) NX002 a
moderately differentiated squamous carcinoma grown from
an endo-bronchial bronchoscopic biopsy, (iii) NX004 an
undifferentiated small cell tumour obtained from a sub-
cutaneous metastasis. All tumours had a doubling time of
10-13 days. Experiments were performed between the 8th
and 10th passage for CX117 and NX002 and at the 3rd
passage for NX004. All tumours maintained their original
histological characteristics on serial passage.
Chemotherapeutic assessments
Xenografts were measured three times weekly with calipers
and tumour volumes calculated assuming an ellipsoid shape
(volume = H/6 x longest diameter x shortest diameter2).
Groups of 6-10 tumours attaining a volume of 0.25-1.Ocm3
were selected for drug testing and allocated by restricted
randomisation to treatment or control groups. The median
doubling time (Td) was estimated for each group and the
therapeutic response was expressed in terms of the specific
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growth delay (SGD) using the equation:
SGD= Td (treated)-Td (control)
Td (control)
The SGD represents the number of doubling times delayed
by treatment (Kopper & Steel, 1975).
TCNU was kindly provided by Leo AB (Helsingborg,
Sweden). It was dissolved in polyethylene glycol (PEG400)
and given by oral gavage at a dose of 20mgkg-1. This
maximum tolerated dose was calculated from LD10
experiments using immune deficient mice. The LD10 dose in
this system was 25mgkg-1.
Results
Activity in xenografts
TCNU given orally (20mgkg-1) caused a delay in the
growth of all three xenografts (Figure 1). Moderate activity
(SGDs of 0.63 and 1.13) was seen in the two non small cell
tumours CX117 and NX002 (Table I). TCNU at this dose
was curative (no tumour palpable 30 days after treatment) in
the small cell xenografts NX004 and in a subsequent
experiment, 50% of that dose (10mgkg-1 orally), was also
curative in this tumour. No treatment deaths or significant
toxicity were observed in any group.
DNA repair enzyme assays
Xenografts were removed using sterile techniques and
immediately snap frozen in liquid nitrogen to be stored at
-80°C until assayed. Tumours were quickly thawed and
minced with scissors to a slurry before the addition of equal
volumes of 300mM KC1, 50mM Tris HC1 (pH7.5), 10mM
dithiothreitol, 1 mM EDTA and 0.5mM phenylmethyl-
sulfonyl fluoride. Cells were disrupted in a Potter hand
homogenizer and debris removed by centrifugation (l0,OOOg
for 30min). Protein concentrations were estimated by the
Coomassie Blue method (Bradford, 1976). 06-methyl-
guanine-DNA methyltransferase activity in the extracts was
assayed by measurement of the disappearance of 06-[3H]
methylguanine from methylated DNA (Karran et al., 1979).
The reaction mixture (500p1) consisted of DNA containing
1,500cpm (1.2pmol 06-methylguanine) in 70mM Hepes
KOH (pH 7.6), 1 mM EDTA, 10mM dithiothreitol, 5%
glycerol and 25-300 ig of crude cell protein extract. Mixtures
were incubated at 37°C for 1 h then chilled and precipitated
with 500,1 cold 0.8 M trichloroacetic acid. After standing at
0°C for 15min, the samples were centrifuged and the
supernatants discarded. The pellets were hydrolysed in 100l i
of 0.1 M HC1 at 70°C for 30min to release all purines from
the DNA. Determination of the HC1 soluble radioactive
material provided estimates of the relative content of 06_
methylguanine.
The activity of 3-methyladenine-DNA glycosylase was
assayed using calf thymus DNA treated with [3 H] dimethyl
sulphate as substrate (Riazuddin & Lindahl, 1978). The
reaction mixture (100I ) consisted of lOg alkylated DNA
(5,000cpm) in 70mM Hepes KOH (pH7.6), 1mM EDTA,
1mM dithiothreitol, 5% glycerol and 12-100 g crude cell
protein extract. Mixtures were incubated at 37°C for 45min
and then chilled before the addition of lO,ul heat denatured
calf thymus DNA (2mg/ml), lO ul of 5M NaCl and 300pI
ethanol. The tubes were mixed and after standing at 0°C for
30min were centrifuged at 10,OOOg for 30min). The
supernatant (200pl) was removed and its radioactivity
determined.
TCNU assay
TCNU was dissolved in PEG400 and administered by
gavage at 20mgkg-1 to 20 fasted tumour bearing mice (10,
NX002; 10, NX004). PEG400 alone was given in the same
volume to a control group. Samples of venous blood,
tumour and lung tissue were taken from each group at 10
and 30min following drug administration. Individual blood
specimens were pooled before the plasma was separated by
centrifugation at 4°C for 10min at 2,500rpm. Aliquots were
stored at -40°C until analysis. Tumours and lungs were
removed, washed in cold 0.1M phosphate buffer (pH6.0),
blotted dry, weighed, frozen in liquid nitrogen and stored at
-40°C. Prior to analysis tumours and lungs were homo-
genised in cold 0.1M phosphate buffer (pH 6.0) to give a
20% weight/volume homogenate. Analysis of TCNU in
plasma and homogenates was by high pressure liquid
chromatography using the method of Polacek et al., 1988
with a modified mobile phase of 0.1% glacial acetic acid in
water/acetonitrile (63/37).
DNA repair enzyme assays
The results of the assays of the two DNA repair enzymes are
illustrated in Figure 2. Demethylation of 06-methylguanine
from alkylated DNA was demonstrated with crude cell
extracts prepared from the two non-small cell xenografts
NX002 and CXI17. These tumours clearly possess the
enzyme 06-methylguanine-DNA methyltransferase and could
be designated Mer+. NX004, the small cell tumour showed
no methyltransferase activity and could be designated
Mer-. This tumour was cured by TCNU. Extracts from all
three xenografts released 3-methyladenine from alkylated
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Figure 1 Effect of TCNU (0) (20mgkg-1 orally on day 0) on
three human lung cancer xenografts (a) CX117, adenocarcinoma
(b) NX002, squamous carcinoma (c) NX004, small cell tumour.
Growth expressed as % of volume on day 0 (mean+s.e.). 6-10
tumours in each group. (Controls, 0).
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Table I Activity of an oral dose of TCNU (20mgkg1) in
two non-small cell lung cancer xenografts
Median Specific
doubling growth
time (days) delay
CX117 (adenocarcinoma)
Controls (n=6) 11 -
TCNU (n=8) 18 0.63
NX002 (squamous)
Controls (n=7) 11 -
TCNU (n= 10) 23.5 1.13
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Figure 2 Estimation of DNA repair enzyme activity in crude
cell extracts from xenografts. *, NX002; *, NX004; *, CX117.
(a) Demethylation of 06-methylguanine in alkylated DNA. (b)
Release of 3-methyladenine from alkylated DNA.
DNA (Figure 2b) demonstrating the presence of the 3-
methyladenine-DNA glycosylase enzyme. This confirmed
that the Mer- result from NX004 was not due to the sample
being inactive.
TCNU assay
Parent TCNU was detectable in the plasma, lungs and
tumours of mice lOmin after oral administration (Table II).
Mean plasma levels fell to-30% of their lOmin value by
Table II Mean concentrations (±s.d.) of TCNU in plasma,
tumour (NX004) and lungs of 10 mice at 10 and 30min
following an oral dose ofTCNU (20mgkg 1)
10 minutes 30 minutes
PLASMA (ngml1) 2714+77 861 + 188
TUMOUR (ngg1) 1519+623 742+265
LUNGS (ngg-1) 2237+38 1407+273
30min. A higher concentration of TCNU was demonstrated
in the lungs compared with the tumour on a ng g- basis.
Levels after 30min in these tissues were 50-60% lower than
at 10min after administration. No parent drug was
detectable in either tumour or lungs after one hour. There
were no significant differences in the amount of TCNU
found in xenografts of different histological type. No TCNU
peaks were seen in chromatographs of samples obtained
from control mice.
Discussion
These experiments have demonstrated that TCNU is active
against human lung cancer xenografts grown in immuno-
deficient mice. Moderate activity was observed in the two
non-small cell tumours with the SGDs obtained being com-
parable with other reports of the activity of alkylating agents
in this tumour type (Steel et al., 1983). The small cell tumour
NX004 appeared to be acutely sensitive to TCNU. This
effect may be explained by the fact that this tumour lacks
the DNA repair protein 06-methylguanine-DNA methyl-
transferase and presumably was unable to inhibit the
formation of DNA crosslinks caused by the drug.
This enzyme is found in foetal and adult human cells
(Waldstein et al., 1982; D'Ambrosio et al., 1987) with a
marked variation noted between individuals (Myrnes et al.,
1983). Mer -ve cells are more sensitive to nitrosoureas than
Mer +ve cells (Day et al., 1980; Erickson et al., 1980) and
clearly the therapeutic index of these drugs may depend on
the relative activity of this enzyme in malignant and non-
malignant tissues. Myrnes and colleagues (1984) examined
this relationship in 24 patients and found that in the
majority of cases, enzyme activity was higher in extracts
from tumours compared with normal cells from the same
organs. It has also been shown recently in mice (Gerson et
al., 1987) that bone marrow precursors have low enzyme
levels which may explain why myelosuppression is often the
dose limiting toxicity observed with nitrosoureas.
TCNU appears to have unique pharmacokinetic properties
compared with other nitrosoureas (Lee et al., 1985;
Gunnarsson et al., 1988). Using an HPLC technique we were
able to demonstrate parent drug in plasma and tissues
10min after an oral dose. TCNU levels fell rapidly in the
next 20min with no drug detectable after 1 h. Studies
looking for metabolites of TCNU are currently in progress
and evidence for its ability to cross the blood-brain barrier
will soon be published (Whittle et al., (1987).
Our studies suggest that TCNU is an interesting
compound with unique pharmacokinetic properties. It
remains to be seen whether the promising activity seen in
preclinical and phase I testing (Smyth et al., 1987; Vibe-
Petersen et al., 1987) will be confirmed in the extensive phase
II trials which are now ongoing.
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